

1 Risk of COVID-19 breakthrough infection and hospitalization in individuals with 2 comorbidities

3 Peter D Smits, PhD¹; Samuel Gratzl, PhD¹, PhD; Michael Simonov, MD^{1,2}; Senthil K
4 Nachimuthu, MD, PhD¹; Brianna M Goodwin, MS¹; Michael D Wang, MD¹; Benjamin M
5 Althouse, PhD, ScM^{1,3,4}; Nicholas L Stucky, MD, PhD^{1, ‡}

6

7 ¹ Truveta Incorporated, Bellevue, WA

8 ² Yale School of Medicine, New Haven, CT

9 ³ Information School, University of Washington, Seattle, WA

10 ⁴ Department of Biology, New Mexico State University, Las Cruces, NM

11

12 ‡ To whom correspondence should be addressed

13 Dr Nicholas L Stucky

14 Truveta, Inc

15 1745 114th Ave SE, Bellevue, WA 98004

16 Email: nicholass@truveta.com

17

18 Keywords: COVID-19; breakthrough infection; comorbid conditions; COVID-19 hospitalization

19

20 Highlights:

- 21 • COVID-19 infection has greater severity in those with comorbidities.
- 22 • Here we investigate the risk of breakthrough infections and hospitalizations in fully-
23 vaccinated individuals with and without comorbidities.
- 24 • We find increased rates of breakthrough infections with all comorbidities, with CKD
25 having the greatest risk.
- 26 • Individuals with chronic lung disease had the highest rate of breakthrough infection, but
27 the lowest subsequent risk of hospitalization.
- 28 • Individuals with comorbidities should remain vigilant against infection even if vaccinated.

29

30 Conflict of Interest: All authors are employees of Truveta, Inc.

31

32 Acknowledgements: The authors thank Mackenzie Bogiages and Ari Robicsek for helpful
33 comments on the manuscript and statistical analyses, and Ian Davies for help with establishing
34 the code repository. This study was funded by Truveta, Inc.

35

36 Ethical Approval: This study was reviewed by the Providence St. Joseph Health Institutional
37 Review Board (IRB) as STUDY2022000212 and determined Not Human Research. 45 CFR
38 46.102(e)(1).

39

40 **Abstract**

41 Background

42 Studies have shown that those with certain high-risk comorbidities such as diabetes, chronic
43 kidney disease (CKD), chronic lung disease, or those with immunocompromising conditions
44 have increased risk of hospitalization from COVID-19. Here we estimate the elevated risks of
45 breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities.

46

47 Methods

48 Using a population of fully-vaccinated patients in the de-identified Truveta Platform of electronic
49 health records from January 1, 2019, to January 10, 2022, we used logistic regression to
50 estimate risk of 1) a patient experiencing a breakthrough COVID-19 infection after being fully
51 vaccinated, and 2) rate of hospitalization in those experiencing breakthrough infection. Potential
52 confounding was adjusted with inverse probability weighting for each comorbidity by age, race,
53 ethnicity, and sex. We present ORs and percentages of breakthrough infections by comorbidity
54 status.

55

56 Results

57 Of 3,424,965 fully vaccinated patients, 2.79%, 2.63%, 2.38%, 1.83% with CKD, chronic lung
58 disease, diabetes, and those in an immunocompromised state experienced breakthrough
59 infection, respectively, compared to 1.95% in the overall population. All comorbidities were
60 associated with significantly increased odds of breakthrough infections and subsequent
61 hospitalizations. Breakthrough infection hospitalizations in populations with comorbidities
62 ranged from 26.43% for CKD to 10.23% for chronic lung disease, with corresponding ORs of
63 2.22 (95% CI: 1.88 - 2.63) and 1.37 (95% CI: 1.21 - 1.55), respectively.

64

65 Conclusions

66 Fully-vaccinated individuals with certain comorbidities experienced increased risk of
67 breakthrough COVID-19 infection and subsequent hospitalizations compared to the general
68 population. Individuals with comorbidities should remain vigilant against infection even if
69 vaccinated.

70

71

72 **Introduction**

73 Reports of declining vaccine effectiveness against COVID-19 after the primary series have
74 driven discussion about booster vaccinations (1,2). On September 24, 2021, Pfizer booster
75 vaccinations were approved based on data showing waning vaccine immunity against infection.
76 On October 21, 2021, the CDC expanded its recommendation to include boosters for Moderna
77 and Janssen vaccines. These decisions were based largely on declines in vaccine effectiveness
78 in the elderly population in both U.S. and Israeli populations (3). The CDC recommended
79 booster vaccinations for people aged 50 or over with high-risk medical conditions while stating
80 that people aged 18-49 with high-risk medical conditions may receive the vaccine based on
81 limited unpublished CDC data (4). Nevertheless, only limited data were available to understand
82 the risk of breakthrough infections (a COVID-19 case despite being fully vaccinated) in people
83 with high-risk medical conditions in the U.S. Prior studies in unvaccinated populations have
84 shown more severe outcomes for COVID-19 infection for people with certain high-risk
85 comorbidities such as diabetes, chronic kidney disease (CKD), or who are
86 immunocompromised, e.g., because of cancer, solid organ transplant, or HIV (5–8).

87 Before the SARS-CoV-2 delta variant became prevalent, one study of 108,720 mostly male U.S.
88 veterans with high-risk conditions showed vaccine effectiveness for preventing infection
89 remained high (>95%) but did not evaluate the risk of severe disease (9). Another study in a
90 similar population did not show an elevated risk of severe outcomes in breakthrough infections
91 (10). In order to better understand the risk of breakthrough infection and severe outcomes in
92 high-risk populations, we the newly developed Truveta Platform to ask whether vaccinated
93 patients with comorbidities have higher rates of breakthrough COVID-19 infection and higher
94 rates of hospitalization following breakthrough infection than in those vaccinated but without the
95 studied comorbidities.

96

97 **Methods**

98 Our study population included a subset of fully vaccinated patients present in the de-identified
99 Truveta electronic health records (EHR) Platform from January 1, 2019, to January 10, 2022
100 (11). This covers patients across Alaska, California, Montana, New Mexico, Oregon, Texas, and
101 Washington. A patient was considered fully vaccinated two weeks after receiving two mRNA
102 vaccine doses (Moderna or Pfizer) or two weeks after receiving a single dose of the Janssen
103 vaccine. Additionally, patients were excluded from our study population if they were missing sex
104 or age fields, experienced a COVID-19 infection prior to being fully vaccinated (i.e., 14 days

105 post last dose of primary series), had no health system encounters following vaccination, were
106 missing their date of being fully vaccinated, were under 12 years of age at time of vaccination,
107 or had any vaccination events prior to December 1st, 2020. These last three criteria likely
108 indicated a recording error in patient age at vaccination or their time of vaccination. All
109 vaccination events were extracted from the EHR from member health systems; these events
110 generally consisted of vaccinations that took place within the health system as well as
111 vaccination records actively pulled from the health system's respective state's Immunization
112 Information System.

113 Comorbidities were defined using Elixhauser comorbidity ICD-10-CM diagnostic codes taken
114 from the patient's medical record (12), and included chronic kidney disease (CKD), chronic lung
115 disease/chronic obstructive pulmonary disease (COPD), diabetes, and those in an
116 immunocompromised state. CKD was defined as the earliest date a patient had an ICD-10-CM
117 diagnostic code consistent with CKD or when Kidney Disease: Improving Global Outcomes
118 (KDIGO) criteria for CKD were met by estimated glomerular filtration rate (eGFR) criteria (13).
119 For each comorbidity of interest, patients with that comorbidity diagnosed prior to being fully
120 vaccinated were compared with patients with none of the comorbidities of interest. Patients who
121 were diagnosed with a comorbidity after being fully vaccinated were excluded from analysis to
122 ensure the risk of breakthrough infection after vaccination was associated with a comorbidity
123 extant before vaccination. The complete list of comorbidity ICD-10 codes is presented in the
124 Supplementary Material.

125 Our response variables of interest were 1) if a patient experienced a breakthrough COVID-19
126 infection at any point after being fully vaccinated, and 2) if a patient who experienced a
127 breakthrough infection was hospitalized. SARS-CoV-2 infection was defined as a patient's first
128 diagnosis of COVID-19 as per ICD-10-CM code (U07.1). COVID-19 hospitalizations were
129 defined as an inpatient encounter where the patient's SARS-CoV-2 positivity fell within the
130 interval of 14 days prior to admission up to the date of discharge.

131 To account for potential confounding, we used inverse probability weighting (IPW) for each of
132 the comorbidities with the following confounding features as predictors: age (<18, 18-49, 50-64,
133 65-74, 75+), race (White, Asian, Black or African American, American Indian or Alaska Native,
134 Native Hawaiian or Other Pacific Islander, Unknown), ethnicity (Hispanic or Latino, Not Hispanic
135 or Latino, and Unknown), and sex. Propensity scores were estimated using logistic regression
136 and transformed into IPWs to estimate the average effect of the comorbidity on those patients'
137 outcomes (i.e., average "treatment" effect in the "treated") (14). IPWs were calculated

138 separately for the breakthrough infection analysis and the hospitalization following breakthrough
139 infection analysis.

140 Event rates were calculated using the weighted data. The proportion of breakthrough cases was
141 calculated as the number of patients with a given comorbidity who experienced a breakthrough
142 COVID-19 infection divided by the total number of patients with that comorbidity to yield a rate,
143 weighted by the IPWs. The confidence interval for this proportion was calculated using the
144 normal approximation of the binomial confidence interval (15). See Supplemental Code at
145 https://github.com/Truveta/smits_et_al_covid_breakthrough_comorbidities.

146 The weighted event rates for the population of patients without any of the comorbidities were
147 different for each of the focal comorbidities because of how each population was weighted to
148 resemble their respective group of patients with the comorbidity. To ease visual comparison, we
149 calculated a composite of these four weighted event rates using a Binomial Generalized Linear
150 Model with only an intercept to estimate an average event rate from these samples. This
151 composite was not used in any statistical comparisons and was only used to ease absolute
152 interpretation of outcomes (e.g., Figure 1). This process was repeated for patients who
153 experienced hospitalization post breakthrough COVID-19.

154 Odds ratios (ORs) of breakthrough infection associated with a comorbidity were calculated
155 using logistic regression weighted using the calculated IPWs. This method was repeated for
156 calculating the OR of hospitalization following breakthrough infection associated with a
157 comorbidity. The confounding demographic features used in the weighting model were included
158 as additional covariates in these regression models. ORs were calculated as the exponentiated
159 regression coefficient (16) for the comorbidity covariate in the logistic regression model. Each
160 comorbidity was analyzed independently. This process was repeated for the analysis of
161 hospitalization following breakthrough infection.

162 Analysis was done using the R programming language (4.1.1)(17) along with the following
163 packages: arrow(18), broom(19), dplyr(20), ggplot2(21), janitor(22), magrittr(23), purrr(24),
164 questionr(25), rlang(26), stringr(27), tableone(28), targets(29), tibble(30), and tidyr(31).

165

166 **Results**

167 Study population

	Sample Size	Change in Sample Size
Raw Sample Size	3424965	—

	Sample Size	Change in Sample Size
No Missing Sex and Vaccination Date	3130114	294851
No Previous COVID-19 Infection	3059106	71008
No Encounters After Vaccination	2262391	796715
No Impossible Times	2109302	153089
No Missing Ages or Ages <= 12 years	2106893	2409
Final Sample Size	2106893	0

168

169 **Table 1:** Study population sample size. Table shows the determination of final sample sized
 170 used in the analysis.

171

172 Our overall study population included 3,424,965 fully vaccinated patients. 1,318,072 patients
 173 were excluded based on inclusion criteria, resulting in 2,106,893 patients for analysis. We
 174 assigned to each patient whether they have a specific comorbidity or are comorbidity-free. This
 175 led to five populations, one for each comorbidity of interest and one comorbidity-free general
 176 population. If a patient has multiple comorbidities, they were assigned to each of the
 177 corresponding comorbidities sub populations, see also the limitations discussion below for
 178 details. Table 1 summarizes the distributions of raw patient counts within each sub population.

179

	General Population (Comorbidity-free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompromised
Overall					
N (fully vaccinated patients)	1,593,780 (100.00%)	109,513 (100.00%)	242,687 (100.00%)	158,284 (100.00%)	159,351 (100.00%)
Breakthrough Case	31,062 (1.95%)	3,055 (2.79%)	6,386 (2.63%)	3,764 (2.38%)	2,922 (1.83%)
Hospitalized for Breakthrough Case	1,856 (0.12%)	806 (0.74%)	653 (0.27%)	633 (0.40%)	466 (0.29%)
Age Group					

	General Population (Comorbidity-free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompromised
<18	72,080 (4.52%)	115 (0.11%)	8,347 (3.44%)	462 (0.29%)	351 (0.22%)
18-49	676,410 (42.44%)	5,748 (5.25%)	72,302 (29.79%)	21,955 (13.87%)	18,960 (11.90%)
50-64	419,257 (26.31%)	18,511 (16.90%)	66,124 (27.25%)	49,188 (31.08%)	42,357 (26.58%)
65-74	262,984 (16.50%)	33,109 (30.23%)	53,051 (21.86%)	47,866 (30.24%)	50,458 (31.66%)
75+	163,049 (10.23%)	52,030 (47.51%)	42,863 (17.66%)	38,813 (24.52%)	47,225 (29.64%)
Sex					
Female	970,513 (60.89%)	58,487 (53.41%)	155,099 (63.91%)	80,571 (50.90%)	93,785 (58.85%)
Male	622,626 (39.07%)	51,004 (46.57%)	87,514 (36.06%)	77,655 (49.06%)	65,531 (41.12%)
Other	641 (0.04%)	22 (0.02%)	74 (0.03%)	58 (0.04%)	35 (0.02%)
Race					
White	1,046,279 (65.65%)	82,647 (75.47%)	187,443 (77.24%)	107,640 (68.00%)	132,706 (83.28%)
Asian	153,193 (9.61%)	7,637 (6.97%)	15,008 (6.18%)	16,269 (10.28%)	8,417 (5.28%)
Black or African American	39,430 (2.47%)	5,706 (5.21%)	9,095 (3.75%)	7,901 (4.99%)	3,826 (2.40%)
American Indian or Alaska Native	10,399 (0.65%)	877 (0.80%)	2,903 (1.20%)	2,129 (1.35%)	1,096 (0.69%)
Native Hawaiian or Other Pacific Islander	6,867 (0.43%)	799 (0.73%)	1,579 (0.65%)	1,574 (0.99%)	569 (0.36%)
Other	337,612 (21.18%)	11,847 (10.82%)	26,659 (10.98%)	22,771 (14.39%)	12,737 (7.99%)
Ethnicity					
Hispanic or Latino	212,628 (13.34%)	9,798 (8.95%)	20,546 (8.47%)	18,711 (11.82%)	8,067 (5.06%)
Not Hispanic or Latino	1,201,147 (75.36%)	95,615 (87.31%)	213,497 (87.97%)	133,524 (84.36%)	145,900 (91.56%)
Other	180,005	4,100 (3.74%)	8,644 (3.56%)	6,049 (3.82%)	5,384 (3.38%)


	General Population (Comorbidity-free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompromised
	(11.29%)				

180 **Table 2:** Baseline characteristics table for each comorbidity population along with the reference
 181 comorbidity-free general population. If a patient has multiple comorbidities, they were assigned
 182 to multiple corresponding comorbidity sub populations. Data represented are unweighted counts
 183 of patients.

184
 185 Percentage of vaccinated with breakthrough case

186 Figure 1 and Table 3 summarize the association between comorbidities and the likelihood of
 187 having a COVID-19 breakthrough infection. Figure 1 shows the percentage of the population
 188 that experienced a breakthrough infection and the ORs of breakthrough infections for individuals
 189 with comorbidities compared to a comorbidity-free population, both calculated from weighted
 190 data. Table 2 includes the results for each individual population as well as the computed
 191 average comorbidity-free general population. In general, we see that those with chronic lung
 192 disease are more likely to have a breakthrough infection (2.63% [95% Confidence Interval:
 193 2.57% - 2.70%], OR: 1.43 [95% CI:1.37 - 1.48]), followed by those with diabetes (2.38% [95%
 194 CI: 2.30% - 2.45%], OR: 1.29 [95% CI: 1.23 - 1.36]).

195



196 **Figure 1:** Left: Percentage of the analyzed vaccinated population that experienced a
 197 breakthrough COVID-19 infection among individuals with comorbidities compared to a
 198 comorbidity-free population. These values are estimated from the propensity score weighted
 199 data. Right: ORs for breakthrough infection associated with having a comorbidity versus having
 200 none of the analyzed comorbidities.

201

Percentage of vaccinated with breakthrough case (95% CI)			
	Comorbidity Population	General Population	OR
Chronic Kidney Disease	2.30% (2.20% - 2.41%)	1.73% (1.64% - 1.82%)	1.34 (1.24 - 1.43)
Chronic Lung Disease	2.63% (2.57% - 2.70%)	1.86% (1.81% - 1.91%)	1.43 (1.37 - 1.48)
Diabetes	2.38% (2.30% - 2.45%)	1.85% (1.78% - 1.92%)	1.29 (1.23 - 1.36)
Immunocompromised	1.83% (1.77% - 1.90%)	1.72% (1.65% - 1.78%)	1.07 (1.01 - 1.13)
General Population		1.77% (1.74% - 1.81%)	


202 **Table 3:** Underlying data table that is used to generate Figure 1. Each cell contains the
 203 estimated value as well as its 95% confidence interval (CI). The average comorbidity-free
 204 general population was computed to simplify the visual representation within the left side of
 205 Figure 1.

206

207 Percentage of breakthrough cases who are hospitalized

208 Figure 2 and Table 3 summarize our results based on the weighted population or risk of
 209 hospitalization from breakthrough infection. In contrast to infection risk, those with CKD were
 210 more likely to be hospitalized from breakthrough infection (26.43% [95% Confidence Interval:
 211 24.43% - 28.54%], OR: 2.22 [95% CI: 1.88 – 2.63]). Differently, those with diabetes and those
 212 immunocompromised patients were the other highest risk groups with 16.82% (95% CI: 15.64%
 213 - 18.06%) and 15.95% (95% CI: 14.65% - 17.34%) hospitalized, respectively, and ORs of 1.81
 214 (95%CI: 1.58 – 2.08), and 1.52 (95%CI: 1.31 – 1.77), respectively.

215



216 **Figure 2:** Left: Percentage of population that experienced hospitalization following a
 217 breakthrough COVID-19 infection among individuals with comorbidities compared to a
 218 comorbidity-free general population. These values are estimated from weighted data. Right:
 219 ORs for hospitalization following a breakthrough infection associated with having a comorbidity
 220 versus having none of the analyzed comorbidities.
 221

Percentage of breakthrough cases who are hospitalized (95% CI)			
	Comorbidity Population	General Population	OR
Chronic Kidney Disease	26.43% (24.43% - 28.54%)	13.91% (12.37% - 15.61%)	2.22 (1.88 - 2.63)
Chronic Lung Disease	10.23% (9.50% - 11.00%)	7.67% (7.03% - 8.35%)	1.37 (1.21 - 1.55)
Diabetes	16.82% (15.64% - 18.06%)	10.05% (9.11% - 11.06%)	1.81 (1.58 - 2.08)
Immunocompromised	15.95% (14.65% - 17.34%)	11.10% (9.99% - 12.30%)	1.52 (1.31 - 1.77)
General Population		8.85% (8.42% - 9.29%)	

222 **Table 4:** Each cell contains the estimated value as well as its 95% confidence interval (CI). The
 223 average comorbidity-free general population was computed to simplify the visual representation
 224 within the left side of Figure 2.

225

226 **Discussion**

227 Here we found that the incidence of SARS-CoV-2 breakthrough infection and COVID-19
228 hospitalization following breakthrough infection were significantly greater among patients with
229 select comorbid medical conditions when compared to the general population. Specifically,
230 people with diabetes, chronic lung disease, or CKD have increased incidence of breakthrough
231 infection compared to the general population after adjusting for age, sex, race, and ethnicity.
232 These conditions are thought to lead to impaired immune function (32–34). This is consistent
233 with studies in unvaccinated people showing higher risk of infection in these populations as well
234 as a study in mostly male U.S. veterans which showed reduced vaccine effectiveness in
235 patients with a high Charlson comorbidity index (9).

236 In our study, patients with comorbidities had nearly twice the odds of being hospitalized than the
237 general vaccinated population. Overall, these findings add to prior studies showing worse
238 outcomes following COVID-19 infection in people who are immunocompromised, with diabetes,
239 CKD, or with chronic lung disease (5–7) and adds additional support for recommendations of
240 booster vaccines given these groups continue to fare worse than the general vaccinated
241 population. One study in an unvaccinated population reported ORs of greater than 2 for in-
242 hospital mortality following COVID-19 infection in patients with diabetes, CKD, or pulmonary
243 disease when compared with the general population (6). We identified CKD as the highest risk
244 comorbidity for hospitalization, even after adjustment for age and demographic factors. Notably,
245 a large study in male U.S. veterans did not show an elevated risk of severe outcomes in
246 breakthrough infections in patients with diabetes, chronic lung disease, or CKD (10). This was
247 possibly due to their study design which matched patients by comorbidity burden thereby
248 reducing any differences between groups. In contrast our study compared patients with
249 identified comorbidities to a control group without these comorbidities and did not exclude or
250 match patients with multiple comorbidities.

251 We found that the immunocompromised group had the smallest increased risk of breakthrough
252 infection compared to the other comorbidities. This is possibly due to a higher adoption of
253 protective behaviors such as social distancing and mask wearing in this group than other groups
254 and the general population. Additionally, while we found that those with chronic lung disease
255 had the highest rate of breakthrough infection (2.63%) it had the lowest rate of hospitalization
256 (10.23%). This might be due to those with COPD having supplemental oxygen and steroids
257 readily available, or that COPD may capture a broad range of disease from very mild asthma to
258 end-stage COPD, therefore attenuating overall risk of hospitalization in our data; though future
259 research is necessary.

260 Like all studies, ours is subject to limitations. First, there are multiple confounding features
261 which are difficult to address with the available data including the timing of patient vaccination,
262 precedent undiagnosed COVID-19 infection, and the timing of infections in relation to SARS-
263 CoV-2 variants of concern. Future studies should correct for these potential confounders.
264 Secondly, our current data definitions rely heavily on ICD-10-CM codes, except for CKD which
265 incorporates lab tests. This limits the scope and may limit the accuracy of our comorbidity
266 groups and COVID-19 diagnoses. For example, adding labs would improve sensitivity for
267 COVID-19 cases. As more data become available, we plan to include SARS-CoV-2 variants of
268 concern, geography, and more comorbidities.

269 Our current outcome models consider only the effect of a single comorbidity on our outcomes of
270 interest. Future iterations of this analysis should consider the effect of multiple simultaneous
271 comorbidities on outcomes as well as their interaction effects. Currently, we treat each
272 comorbidity as purely independent, but it is known that patients can have multiple comorbidities
273 (e.g., diabetes and CKD). Future research could consider the interaction effects of patients
274 having multiple comorbidities on probabilities of outcome events; specifically, models of
275 breakthrough infection and hospitalization outcomes should consider how the interactions
276 among these comorbidities may contribute to differences in odds of breakthrough infection and
277 hospitalization.

278 As vaccinated individuals continue to make decisions about booster vaccinations, they will be
279 looking for information regarding their personal risk of breakthrough COVID-19 infection and
280 severe outcomes like hospitalization. The FDA and CDC both made recommendations to
281 include high-risk groups, such as those we studied, as groups who should receive booster
282 vaccinations. While there is robust data showing increased risk to unvaccinated groups with
283 comorbidities, both the FDA and CDC cited limited data in vaccinated groups with comorbidities.
284 The findings of this study improve the evidence and support recommendations for people with
285 comorbidities such as chronic kidney disease, chronic lung disease, diabetes or people who are
286 immunocompromised to receive the primary vaccination sequence as well as a booster dose.

287

288

289 References

- 290
- 291 1. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, et al. Comparison of two highly-
- 292 effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence [Internet]. *Public*
- 293 *and Global Health*; 2021 Aug [cited 2021 Oct 27]. Available from:
- 294 <http://medrxiv.org/lookup/doi/10.1101/2021.08.06.21261707>
- 295 2. Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, et al. Resurgence of SARS-CoV-2
- 296 Infection in a Highly Vaccinated Health System Workforce. *N Engl J Med*. 2021 Sep 30;385(14):1330–2.
- 297 3. Oliver, Sara. ACIP Presentation Slides: Sept 22-23, 2021 , Evidence to Recommendation Framework: Pfizer-
- 298 BioNTech COVID-19 Booster Dose. Available from:
- 299 <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-9-23/03-COVID-Oliver.pdf>
- 300 4. Dooling K. ACIP Presentation Slides: Oct 21, 2021, Evidence to Recommendation Framework: Moderna &
- 301 Janssen COVID-19 Vaccine Booster Dose. Available from:
- 302 <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/11-COVID-Dooling-508.pdf>
- 303 5. Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz B, Zink RC, et al. Patient Characteristics and
- 304 Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United
- 305 States. *Clin Infect Dis*. 2021 May 18;72(10):e558–65.
- 306 6. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S, Sequí-Dominguez I,
- 307 et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis
- 308 exploring differences by age, sex and health conditions. Verdonck K, editor. *PLOS ONE*. 2020 Nov
- 309 3;15(11):e0241742.
- 310 7. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A
- 311 systematic review and meta-analysis. *J Infect*. 2020 Aug;81(2):e93–5.
- 312 8. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer
- 313 and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. *Eur J Cancer*. 2020
- 314 Nov;139:43–50.
- 315 9. Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National
- 316 Population in a Real-World Setting. *Ann Intern Med*. 2021 Oct;174(10):1404–8.
- 317 10. Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2 infection after
- 318 vaccination in a high-risk national population. *EClinicalMedicine*. 2021 Oct;40:101117.
- 319 11. Truveta. Truveta Platform. [cited 2021 Oct 27]; Available from: <http://truveta.com>
- 320 12. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity Measures for Use with Administrative Data: *Med*
- 321 *Care*. 1998 Jan;36(1):8–27.
- 322 13. Chapter 1: Definition and classification of CKD. KDIGO 2012 Clin Pract Guidel Eval Manag Chronic Kidney Dis.
- 323 2013 Jan 1;3(1):19–62.
- 324 14. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in
- 325 Observational Studies. *Multivar Behav Res*. 2011 May 31;46(3):399–424.
- 326 15. Agresti A. *Categorical data analysis*. 3rd ed. Hoboken, NJ: Wiley; 2013. 714 p. (Wiley series in probability and
- 327 statistics).
- 328 16. Gelman A, Hill J, Vehtari A. *Regression and other stories*. Cambridge, United Kingdom: Cambridge University
- 329 Press; 2021. 534 p. (Analytical methods for social research).
- 330 17. R Core Team. *R: A Language and Environment for Statistical Computing* [Internet]. Vienna, Austria: R
- 331 Foundation for Statistical Computing; 2021. Available from: <https://www.R-project.org/>

- 332 18. Richardson N, Cook I, Crane N, Keane J, François R, Ooms J, et al. arrow: Integration to “Apache” “Arrow”
333 [Internet]. 2021. Available from: <https://CRAN.R-project.org/package=arrow>
- 334 19. Robinson D, Hayes A, Couch S. broom: Convert Statistical Objects into Tidy Tibbles [Internet]. 2021. Available
335 from: <https://CRAN.R-project.org/package=broom>
- 336 20. Wickham H, François R, Henry L, Müller K. dplyr: A Grammar of Data Manipulation [Internet]. 2021. Available
337 from: <https://CRAN.R-project.org/package=dplyr>
- 338 21. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New York; 2016. Available
339 from: <https://ggplot2.tidyverse.org>
- 340 22. Firke S. janitor: Simple Tools for Examining and Cleaning Dirty Data [Internet]. 2021. Available from:
341 <https://CRAN.R-project.org/package=janitor>
- 342 23. Bache SM, Wickham H. magrittr: A Forward-Pipe Operator for R [Internet]. 2020. Available from:
343 <https://CRAN.R-project.org/package=magrittr>
- 344 24. Henry L, Wickham H. purrr: Functional Programming Tools [Internet]. 2020. Available from: <https://CRAN.R-project.org/package=purrr>
345
- 346 25. Barnier J, Briatte F, Larmarange J. questionr: Functions to Make Surveys Processing Easier [Internet]. 2021.
347 Available from: <https://CRAN.R-project.org/package=questionr>
- 348 26. Henry L, Wickham H. rlang: Functions for Base Types and Core R and “Tidyverse” Features [Internet]. 2021.
349 Available from: <https://CRAN.R-project.org/package=rlang>
- 350 27. Wickham H. stringr: Simple, Consistent Wrappers for Common String Operations [Internet]. 2019. Available
351 from: <https://CRAN.R-project.org/package=stringr>
- 352 28. Yoshida K, Bartel A. tableone: Create “Table 1” to Describe Baseline Characteristics with or without Propensity
353 Score Weights [Internet]. 2021. Available from: <https://CRAN.R-project.org/package=tableone>
- 354 29. Landau W. The targets R package: a dynamic Make-like function-oriented pipeline toolkit for reproducibility and
355 high-performance computing. *J Open Source Softw.* 2021 Jan 15;6(57):2959.
- 356 30. Müller K, Wickham H. tibble: Simple Data Frames [Internet]. 2021. Available from: <https://CRAN.R-project.org/package=tibble>
357
- 358 31. Wickham H. tidyr: Tidy Messy Data [Internet]. 2021. Available from: <https://CRAN.R-project.org/package=tidyr>
- 359 32. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the
360 factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific
361 infections. *Diabete Metab.* 1992 Jun;18(3):187–201.
- 362 33. O’Dwyer DN, Dickson RP, Moore BB. The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung
363 Disease. *J Immunol.* 2016 Jun 15;196(12):4839–47.
- 364 34. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of Uremia on Structure and Function of Immune System. *J Ren
365 Nutr.* 2012 Jan;22(1):149–56.
- 366